John Haurum

Chairman of the Board

In addition to Agomab, John is the chair of the board of Adcendo (DK), CatalYm (DE), Solid Therapeutics (DK), and Synklino (DK), as well as a non-executive director of Neophore and Storm (both UK). Prior, he was the CEO of F-star Therapeutics in Cambridge, UK (2012-18), VP Research at ImClone Systems, New York (2010-12), and Chief Scientific Officer and Co-Founder of Symphogen, Denmark (2000-09). After his medical degree in Aarhus, Denmark, John received a DPhil in Immunology from University of Oxford, England.

By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.